Self administration of Sq for AMD.
Could it be a window into a broad use license for cancer?
Consider Biogen’s Avonex for MS. This requires self administration and the folks I know use bigger hypos than most diabetics do. (True, the MS patient population is probably younger than the AMD population would be.)
Could one strategy be to get Sq out into AMD patients that take it constantly in low doses (weekly, biweekly, monthly) and then follow them for reduced incidence of cancers? Transforming a big market into one several orders of magnitude larger. Once Sq comes off patent, the market would be so large that name recognition would retain value.
Could a potential partner that is comfortable with such a drug (Biotin?) have suggested the low dose be entered into the clinical protocols?
Speculative yes, but inconsistent with what is known?
Regards,
Market Data 
Markets 
AI
